Can You Still Get a PSA Test on the NHS?

Blog · Cancer

Can You Still Get a PSA Test on the NHS?

By Vitae Team ·

Two prostate screening decisions landed in 2026 and got conflated. What changed in August, what didn't, and what you can still ask for.

Two separate things happened to prostate cancer testing in 2026, three months apart, and they have been tangled together since. One was a recommendation to start screening a small group of men. The other was the quiet withdrawal of a 24-year-old framework that set out how GPs should handle every other man who asked. The headlines said men had lost the right to a test. The government maintains that access policy has not changed. The more precise position is that the national guidance supporting informed choice has demonstrably changed, while the ability to ask has not.

TL;DR

  • You can still ask. The NHS states that men and anyone with a prostate can ask a GP about PSA testing, and that the benefits and risks will be discussed before a decision is made. The symptomatic pathway is untouched.
  • Routine testing is still not offered, the NHS says, with one exception: men found through genetic testing to carry a faulty BRCA2 gene.
  • What was withdrawn is the framework around asking. The Prostate Cancer Risk Management Programme, in place since 2002, was withdrawn entirely in August 2026. It had given asymptomatic men aged 50 and over a nationally recognised route to a test after discussing the pros and cons with a GP.
  • Age still matters clinically. NHS information continues to list age as a risk factor, noting risk increases with age and mostly affects men over 50. What changed is the testing framework built around that age, not the risk.
  • The new screening offer is narrow. PSA every two years for men aged 45 to 61 with a pathogenic BRCA2 variant and a relevant family history, accepted for England in June 2026, with rollout expected from 2027.
  • Black men were left out for lack of evidence, not lack of risk. Their overall risk is substantially higher, but the committee judged the evidence insufficient to establish whether screening would do more good than harm for them.

What changed in 2026

The first decision came on 28 May, when the UK National Screening Committee published its final recommendation. It advised against screening the whole male population, and in favour of a targeted programme: a PSA test every two years for men aged 45 to 61 who have a confirmed pathogenic BRCA2 variant together with a family history of breast, ovarian, pancreatic or prostate cancer. The government accepted that for England on 2 June, with rollout expected from 2027 rather than guaranteed for any particular date. Scotland, Wales and Northern Ireland make their own decisions and were still considering it.

That narrowed the committee's own November 2025 draft, which had covered BRCA1 and BRCA2 carriers together. BRCA1 was dropped after consultation and further modelling, because the raised risk of fast-growing disease that holds for BRCA2 carriers did not hold consistently for BRCA1. Targeted screening was not recommended for men with a family history but no BRCA2 variant, nor for Black men.

The second decision arrived in August and received far less careful coverage. The Department of Health and Social Care confirmed that the Prostate Cancer Risk Management Programme had been withdrawn in its entirety, following the government's acceptance of the screening recommendation. Patient information would come through NHS channels instead, and guidance for GPs through the NICE Clinical Knowledge Summaries. The symptomatic pathway was explicitly unchanged. The old programme's own web page now redirects to the NHS page on the PSA test.

So can you still ask?

Yes, and the NHS says so in plain terms: men and anyone with a prostate can ask a GP about PSA testing, and the doctor will discuss the benefits and risks before a decision is made. The same page is equally plain about the limit — routine PSA testing is not currently offered on the NHS, the exception being men found through genetic testing to carry a faulty BRCA2 gene. If you have symptoms such as urinary changes, blood in urine or semen, or unexplained pain in the lower back, hips or pelvis, that route is entirely unaffected and you should use it now.

What has gone is the scaffolding around the request. The withdrawn programme set out a nationally recognised route: an asymptomatic man aged 50 or over who had discussed the benefits and harms with his GP could have the test. It also instructed GPs not to raise the subject proactively, which is why the arrangement was always called informed choice rather than screening. Removing the programme removes both halves — the age-based prompt that gave men a reason to start the conversation, and the dedicated national framework telling GPs how to finish it.

Prostate Cancer Research, which has pressed the department for clarification, makes the sharper point: the replacement materials no longer explicitly state that higher-risk men can request a PSA test, so it is unclear how requests will be handled. The charity notes that even under the old programme, higher-risk men were often refused. Other NHS and clinical guidance remains in use, and some local primary care resources still carry the old age-50 wording — so this is not a vacuum, but the single national reference point has gone.

What the row got wrong on both sides

"Men have lost the right to a prostate cancer test" overstates it. Nobody has removed your ability to ask, and the NHS still describes a discussion ending in a decision. What existed before was a nationally recognised route following an informed discussion, not an entitlement you could insist on regardless of clinical judgement.

"Nothing has changed" understates it just as badly. A programme that ran for 24 years was withdrawn, the age-based prompt inside it was dropped, and the sentence telling men over 50 they could come and discuss a test no longer appears in national guidance. The department's position — that the previous guidance was ambiguous and was retired for that reason — is a reasonable argument for the change. It is not an argument that nothing happened.

Why the committee said no to screening everyone

All of this follows from the test rather than from any reluctance to spend money. PSA is prostate-specific but not cancer-specific: levels rise with benign prostate enlargement, with infection, after recent ejaculation and after vigorous exercise or cycling. Many men with a raised PSA do not have prostate cancer — Cancer Research UK puts it at around eight in ten, though the proportion shifts with the threshold used and the population tested — and the test also misses some cancers that are there.

The harder problem is what happens when it finds something real. A large share of prostate cancers grow so slowly that they would never have caused symptoms in a man's lifetime, but once detected they are difficult to ignore, and the investigation and treatment that follow carry their own costs, including long-term effects on bladder control and erectile function. Screening a whole population means accepting a good deal of that in exchange for a smaller number of deaths prevented. The committee's judgement was that for men in general, and for men with a family history but no BRCA2 variant, the balance tipped the wrong way.

That is defensible and uncomfortable at once, because the men it fails are identifiable afterwards while the men spared an unnecessary biopsy never learn they were. Screening decisions trade a visible harm against an invisible benefit, which is why they read as callousness. Our piece on what "aggressive but early" means covers the case for catching fast-growing disease early.

Black men, family history, and the gap in the evidence

The decision that has drawn most criticism is the one on Black men, and it turns on a distinction worth getting right. Black men face a substantially higher overall risk of prostate cancer and are diagnosed younger on average. That is not disputed, and NHS information lists Black African and African Caribbean ethnicity among the risk factors. What the committee concluded was that the available evidence was insufficient to establish whether targeted screening of this group would produce more benefit than harm — a judgement covering screening performance, clinically significant disease and potential harms together, rather than one missing statistic.

Higher risk and insufficient evidence are therefore both true at once, and the evidence is thin because Black men have been badly under-represented in research. That is an argument for fixing the research rather than for inaction, and it is being addressed: in June 2026 the government funded an expansion of Prostate Cancer UK's TRANSFORM trial so that all eligible Black men aged 45 to 74 without a recent PSA test can be invited to its later stages. Men cannot self-refer, and invitations come in stages.

For men with a family history and no BRCA2 variant, the position is similar but less advanced. The department says it is working with Cancer Research UK, the Royal College of General Practitioners and the UK Cancer Genetics Group on further advice for GPs handling asymptomatic men worried about their family history.

What This Actually Means

If you are in the targeted group — a known pathogenic BRCA2 variant plus a relevant family history, aged 45 to 61 — a programme is coming in England from 2027, and it is worth knowing it exists because how eligible men will be identified and invited has not been settled.

If you are not, and you are worried, the substance of your position is close to what it was and the paperwork behind it is thinner. Book the appointment and be specific about why: age is still a recognised risk factor, and so are family history, Black African or African Caribbean ethnicity and a known gene variant — but the guidance that turned age 50 into a reason to come in has gone, so the case is made in the room rather than on paper. Ask about benefits and drawbacks rather than for the test alone, since the discussion still has a framework around it.

And if you have been told this month that men have lost the right to be tested, that is not quite what happened. Something real was withdrawn, and the thing most men assumed they had was always conditional on a conversation with a GP who agreed. Knowing which of those you are asking for makes the appointment go better.

Frequently Asked Questions

Can I still ask my GP for a PSA test?

Yes. The NHS states that men and anyone with a prostate can ask a GP about PSA testing, and that the benefits and risks will be discussed before a decision is made. What no longer exists is the national guidance saying that any asymptomatic man over 50 could come in specifically to discuss having one.

Does age still matter?

Yes. NHS information continues to list age as a risk factor and notes that prostate cancer mostly affects men over 50. What changed is the testing framework that used age 50 as its trigger, not the underlying risk.

Who qualifies for the new NHS screening programme?

Men aged 45 to 61 with a confirmed pathogenic BRCA2 variant and a family history of breast, ovarian, pancreatic or prostate cancer, who will be offered a PSA test every two years. England accepted the recommendation in June 2026 and rollout is expected from 2027.

Is there anything I should do before a PSA test?

The NHS advises avoiding ejaculation, anal sex, strenuous exercise and cycling for 48 hours beforehand, since all can raise PSA levels and make the result less accurate. If you have had a urine infection, wait four to six weeks after it clears. You can eat and drink as normal.

The Bottom Line

Two 2026 decisions have been reported as one. The screening recommendation adds a narrow programme for men with a BRCA2 variant and a relevant family history, expected in England from 2027. The August withdrawal removed the 24-year-old framework that gave every other man over 50 a nationally recognised reason to ask, without removing the ability to ask — the NHS still says you can raise it with a GP, and still says routine testing is not offered. So the conversation remains available, the paper case for starting it is weaker, and whether access becomes less consistent is an open question rather than a settled loss.

This article is for general information and is not medical advice. If you have symptoms or are concerned about your prostate cancer risk, speak to your GP.

Sources

  • NHS. PSA test. https://www.nhs.uk/tests-and-treatments/psa-test/
  • NHS. Prostate cancer — causes. https://www.nhs.uk/conditions/prostate-cancer/causes/
  • Cancer Research UK. UK NSC recommends prostate cancer screening for men with a BRCA2 gene change and family history of cancer, 28 May 2026 (updated 2 June 2026). https://news.cancerresearchuk.org/2026/05/28/uk-nsc-recommends-prostate-cancer-screening-for-men-with-a-brca2-gene-change-and-family-history-of-cancer/
  • Prostate Cancer Research. New guidance raises concerns on access to PSA testing, 18 August 2026. https://www.prostate-cancer-research.org.uk/new-guidance-raises-concerns-on-access-to-psa-testing/
  • Pulse Today. NSC advises against whole-population prostate cancer screening in final recommendation. https://www.pulsetoday.co.uk/news/clinical-areas/renal-medicine-urology-mens-health/nsc-advises-against-whole-population-prostate-cancer-screening-in-final-recommendation/
  • Prostate Cancer UK. UK NSC recommendation: FAQs for health professionals. https://prostatecanceruk.org/for-health-professionals/for-my-role/nsc-faqs-for-health-professionals
  • Prostate Cancer Research. UK NSC confirmed its recommendation to restrict prostate cancer screening to men with known BRCA2 gene variants. https://www.prostate-cancer-research.org.uk/uk-nsc-confirmed-recommendation-to-restrict-prostate-cancer-screening-2/